Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
190
-
Total 13F shares, excl. options
-
48.9M
-
Shares change
-
-2.68M
-
Total reported value, excl. options
-
$446M
-
Value change
-
-$14.7M
-
Put/Call ratio
-
0.58
-
Number of buys
-
97
-
Number of sells
-
-95
-
Price
-
$9.12
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q2 2025
248 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q2 2025.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 190 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.9M shares
of 62.7M outstanding shares and own 78.01% of the company stock.
Largest 10 shareholders include Madison Avenue Partners, LP (6.08M shares), BlackRock, Inc. (4.55M shares), VANGUARD GROUP INC (3.27M shares), Hudson Bay Capital Management LP (1.95M shares), D. E. Shaw & Co., Inc. (1.92M shares), Balyasny Asset Management L.P. (1.52M shares), GEODE CAPITAL MANAGEMENT, LLC (1.36M shares), ALPINE ASSOCIATES MANAGEMENT INC. (1.27M shares), STATE STREET CORP (1.17M shares), and 683 Capital Management, LLC (1.15M shares).
This table shows the top 190 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.